Contineum Therapeutics · Small Molecule · Phase 1/2
CompletedTherapeutic
Population
Adults · 18–75 years
Bilateral SNHL with speech-in-noise deficits
Evidence
trial
Confidence
86%
Indications
Hearing LossSensorineural Hearing LossHidden Hearing LossCochlear Synaptopathy
